

[Press release]



ESSEX BIO-TECHNOLOGY LIMITED **億勝生物科技有限公司**

(Stock Code: 1061)

Essex Bio-Technology Included in Forbes Asia's Best Under A Billion 2020

Hong Kong, 23 November 2020

Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) is pleased to announce that the Group is humble and honoured for being included in 2020 Forbes Asia's Best Under A Billion list, a testimony to the Group's achievements over the past few years.

Forbes Asia's Best Under A Billion list spotlights 200 top performing publicly listed companies in the Asia-Pacific region with sales under \$1 billion. From a universe of some 18,000 small and mid-sized companies in the region, these 200 Best Under A Billion companies have track records of exceptional corporate performance. Companies on the list were selected based on a composite score that incorporated their overall track record in measures such as debt, sales and earnings growth over both the most recent fiscal one- and three-year periods, and the strongest one- and five-year average returns on equity. The criteria also ensured a geographic diversity of companies from across the region.

The Group is encouraged on being conferred the prestigious award and would like to extend its gratitude and appreciations to all stakeholders for their contributions over the years. The Group will continue to strive pragmatically to deliver unmet therapeutics, especially in ophthalmology and wound care and healing, and to strengthen its market access capability for sustainable growth and enhancing shareholder value.

~ End ~

About Essex

Essex Bio-Technology Limited is a bio-pharmaceutical company that develops, manufactures and commercialises genetically engineered therapeutic rb-bFGF (FGF-2), having six commercialised

biologics marketed in China since 1998. The products of the Company are principally prescribed for the treatment of wounds healing and diseases in Ophthalmology and Dermatology, which are marketed and sold through approximately 8,880 hospitals and managed directly by its 43 regional sales offices in China. Leveraging on its in-house R&D platform in growth factor and antibody, the Company maintains a pipeline of projects in various clinical stages, covering a wide range of fields and indications.

Contact

IR: Investors@essex.com.cn

PR: Media@essex.com.cn